Related Experiment Video
Updated: Oct 1, 2026

Fat Preference: A Novel Model of Eating Behavior in Rats
Published on: June 27, 2014
Changes in UCP2, PPARgamma2, and c/EBPalpha gene expression induced by a neuropeptide Y (NPY) related receptor
J Margareto1, I Rivero, A Monge
1Department of Physiology and Nutrition, University of Navarra, Pamplona, Spain.
Abstract:
Neuropeptide Y (NPY), a peptide released by nervous cells, appears to contribute to adiposity regulation by increasing food intake and inhibiting lipolysis. New NPY receptor related antagonists such as S.A.0204 are being developed as potential anti-obesity drugs affecting adipocyte lipid metabolism and thermogenesis. In this sense, those animals fed on a high-energy yielding (cafeteria) diet decreased body fat weight as compared to overweight controls, when they were administered with S.A.0204, and increased body temperature, which statistically correlated with high UCP2 mRNA expression levels in white adipose tissue. In addition, the in vivo NPY-antagonist administration was able to prevent white adipose tissue growth in animals fed the cafeteria (high-fat) diet by impairing PPARy and CIEBPalpha mRNA expression in white fat cells. In summary, this novel NPY related-antagonist S.A.0204 may regulate body fat deposition by affecting both energy dissipation and white adipose tissue deposition, representing a potential new pharmacological strategy for obesity management.
Insights
A novel Neuropeptide Y (NPY) antagonist, S.A.0204, reduced body fat and increased body temperature in animal models. This compound shows potential as an anti-obesity drug by impacting energy expenditure and fat deposition.
Area of Science:
- Endocrinology
- Metabolic Research
- Pharmacology
Background:
- Neuropeptide Y (NPY) plays a role in regulating body fat by influencing appetite and fat breakdown.
- Obesity management strategies are exploring new therapeutic targets, including NPY receptors.
Purpose of the Study:
- To investigate the anti-obesity potential of a novel NPY receptor antagonist, S.A.0204.
- To evaluate the effects of S.A.0204 on adipocyte lipid metabolism, thermogenesis, and fat deposition.
Main Methods:
- Administration of S.A.0204 to animals on a high-energy diet.
- Measurement of body fat weight, body temperature, and gene expression (UCP2, PPARy, CIEBPalpha) in white adipose tissue.
Main Results:
- S.A.0204 administration decreased body fat weight and increased body temperature in animals on a high-energy diet.
- Increased UCP2 mRNA expression in white adipose tissue correlated with elevated body temperature.
- S.A.0204 prevented white adipose tissue growth by impairing PPARy and CIEBPalpha mRNA expression.
Conclusions:
- The NPY antagonist S.A.0204 demonstrates potential for obesity management.
- S.A.0204 may regulate body fat by influencing energy dissipation and white adipose tissue deposition.
- This compound represents a promising pharmacological strategy for combating obesity.
Related Concept Videos
Regulation of Food Intake
GPCRs Regulate Adenylyl Cylase Activity
Two...

